Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
aboutBotox, Academy, acute, alter, andAmerge, APA, arbitration, Arden, aura, automatically, automotive, Avanir, Balloon, bankruptcy, Banner, barring, baseball, belief, BIB, bid, bidding, bovine, breast, bridge, buyout, cardiovascular, Cartwright, cease, certainBotox, chair, charitable, ChinaBotox, clearance, cliff, clothing, cluster, collagen, commercializePosurdex, competitor, conspired, consummate, consummated, consummation, contingen, contrary, conventional, Council, coverage, daily, death, decease, department, dermal, devote, Diradoorian, diverse, diversion, divestReloxin, documentary, DOJ, effectuate, Elizabeth, EMEA, enhance, enjoined, equitable, Ernst, exhaustive, expiry, explanatory, FAS, filler, forCombigantm, formafootnote, Foundation, fromCombigantm, fromPrevagetm, fulfill, Glaxo, GlaxoSmithKline, GSK, hard, Hart, Hospital, HSR, hyaluronic, hydrochloride, hypertrophy, hypothetical, idiopathic, impracticable, inaccurate, inclusion, Inspector, intervention, Intragastric, Kagaku, Kenkyusho, launchedElestat, Lavigne, length, lost, manufactureBotox, marketBotox, marketingPrevagetm, marketingRestylane, mastectomy, MD, meaningful, memory, Merage, merged, migraine, mirror, MMA, molded, morbid, mortgage, MRI, multinational, naratriptan, neurogenic, NPS, obesity, obtainedPosurdex, ofPrevagetm, ofReloxin, oilfield, ongoingBotox, ourPosurdex, outpatient, overruled, Paul, Pby, persuade, PhRMA, preclude, predecessor, predetermined, preliminary, premerger, prestige, Prevage, productAvage, productsImitrexSTATdose, promoteBotox, pronouncement, prophylactic, proration, prostatic, QSR, Raymond, reargument, reconsideration, reconstructive, redundant, refurbishment, regain, registry, reintroduce, relicense, reluctant, remand, remanded, remanding, renegotiating, reorganization, replace, resolution, retrospective, Rodino, Roundtable, Sanwa, shorter, showing, silicone, Sirna, social, statementspro, stemming, step, subset, succeeding, succinate, sumatriptan, surpassed, surviving, susceptible, switch, Syntaxin, tender, tendered, theReloxin, thereon, thereunder, thirty, toBotox, toReloxin, travel, UCI, unconstitutional, underperforming, undisturbed, unenforceable, vacate, vacated, Volcom, waiting, Winning, Young
Removed:
actinic, affecting, agonist, andRefresh, Arnold, ASTI, BankAmerica, BCG, Biotech, borrowed, Boston, bothAlphagan, brandt, calculating, cancer, Centre, channel, classified, closure, Columbia, consisting, consortium, created, culminating, discontinue, dismissal, enforce, equally, eric, ESOP, exit, extension, facilitate, failing, favorably, Fenner, formally, full, functionally, Gamble, growing, half, hypo, impaired, informational, inherently, initiate, investigating, Irena, karen, Klein, loan, marketsTazorac, Medavoy, Microbiology, Mike, misleading, misrepresentation, negligence, negligent, occurring, osar, Paulo, Peplin, Pharmacia, Pierce, prejudice, pro, protracted, receptor, regardingLumigan, regime, relevant, remain, repetition, researching, resolving, retinoid, rosso, salary, Sao, Schiavo, sellBotox, separation, shareholder, shipping, Squibb, strict, timeline, tort, unrelated, upheld, utilized, voluntarily
Filing tables
Filing exhibits
Related press release
Allergan similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-102425, 333-99219, 333-50524, 33-69746, 33-55061; Form S-4 No. 333-129871; and Form S-8 Nos. 333-117939, 333-117937, 333-117936, 333-117935, 333-65176, 333-43584, 333-43580, 333-94157, 333-94155, 333-70407, 333-64559, 333-25891, 333-04859, 333-09091, 33-66874, 33-48908, 33-44770, 33-29528, 33-29527) of Allergan, Inc. and in the related Prospectuses of our reports dated March 2, 2006, with respect to: (1) the consolidated financial statements and schedule of Allergan, Inc., and (2) Allergan, Inc. management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Allergan, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2005.
/s/ Ernst & Young LLP
Orange County, California
March 2, 2006
March 2, 2006